Skip to main content
padlock icon - secure page this page is secure

SIRCLE: a randomised controlled cost comparison of self‐administered short‐course isoniazid and rifapentine for cost‐effective latent tuberculosis eradication

Buy Article:

$52.00 + tax (Refund Policy)

Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9‐month course of isoniazid (9H). A 3‐month course of weekly isoniazid and rifapentine (3HP) has been shown to be as effective as 9 months of daily isoniazid, and associated with less hepatotoxicity; however, rifapentine is not currently available in Australia. Introduction of this regimen would have apparent advantages for people with LTBI in Victoria by safely shortening duration of LTBI therapy. However, the cost benefit of this new therapeutic approach is uncertain.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: antitubercular agents; controlled clinical trial; latent tuberculosis; preventative medicine; tuberculosis

Document Type: Research Article

Publication date: December 1, 2017

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more